---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-056018"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2023-10-27T23:59:59+00:00"
generated_at: "2026-06-09T07:32:50.576498+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FibroGen receives Nasdaq notice of non-compliance for bid price below $1.00

## Summary
- Closing bid price of FGEN stock below $1.00 for 30 consecutive business days as of Oct 24, 2023.
- Company has 180 calendar days (until April 22, 2024) to regain compliance.
- To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.
- If not cured, FibroGen may qualify for an additional 180-day period if other listing standards met.
- FibroGen states it meets all other Nasdaq continued listing requirements except bid price.

## SEC filing metadata
- accession: 0000950170-23-056018
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2023-10-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017023056018/0000950170-23-056018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017023056018/fgen-20231024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-056018
- JSON: https://secwatch.observer/filing/0000950170-23-056018.json
- Plain text: https://secwatch.observer/filing/0000950170-23-056018.txt

## Key facts
- Listing & Compliance Notices
  KYNTRA BIO, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: October 24, 2023, FibroGen, Inc. (“FibroGen”) received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying FibroGen that for the last 30 consecutive business days the bid price of FibroGen’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listing of FibroGen’s common stock on Nasdaq. In accordance with listing rule 5810(c)(3)(A), FibroGen has 180 calendar days, or until April 22, 2024, to r
  evidence_url: https://www.sec.gov/Archives/edgar/data/921299/000095017023056018/0000950170-23-056018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.